BioGaia (BIOG B) Stock Overview
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
BIOG B Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
BioGaia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 103.80 |
| 52 Week High | SEK 139.70 |
| 52 Week Low | SEK 93.20 |
| Beta | 0.66 |
| 1 Month Change | -4.07% |
| 3 Month Change | 5.70% |
| 1 Year Change | -0.19% |
| 3 Year Change | 18.63% |
| 5 Year Change | 9.73% |
| Change since IPO | 1,213.93% |
Recent News & Updates
Recent updates
Launch Of Gastrus PURE ACTION And Direct Operations Will Strengthen Future Prospects
Direct market investments and internalizing operations in key regions enhance revenue potential by reducing reliance on distributors and capturing full retail margins.BioGaia's (STO:BIOG B) Soft Earnings Don't Show The Whole Picture
Oct 29
BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90
Apr 25BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 09BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90
Mar 26BioGaia (STO:BIOG B) Will Pay A Larger Dividend Than Last Year At SEK6.90
Mar 09BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90
Feb 24BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's
Feb 10Here's Why We Think BioGaia (STO:BIOG B) Might Deserve Your Attention Today
Nov 27Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Sep 13Does BioGaia (STO:BIOG B) Deserve A Spot On Your Watchlist?
Jun 02A Look At The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Apr 27Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?
Jan 14Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?
Aug 26Does This Valuation Of BioGaia AB (publ) (STO:BIOG B) Imply Investors Are Overpaying?
Jul 24Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Apr 02BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 21Need To Know: Analysts Are Much More Bullish On BioGaia AB (publ) (STO:BIOG B) Revenues
Feb 09BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's
Feb 07Shareholder Returns
| BIOG B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -1.5% | -2.8% | 2.9% |
| 1Y | -0.2% | -22.1% | 2.2% |
Return vs Industry: BIOG B exceeded the Swedish Biotechs industry which returned -8.5% over the past year.
Return vs Market: BIOG B underperformed the Swedish Market which returned 2.3% over the past year.
Price Volatility
| BIOG B volatility | |
|---|---|
| BIOG B Average Weekly Movement | 3.0% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.9% |
| 10% least volatile stocks in SE Market | 2.9% |
Stable Share Price: BIOG B has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BIOG B's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 238 | Theresa Agnew | www.biogaiagroup.com |
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula.
BioGaia AB (publ) Fundamentals Summary
| BIOG B fundamental statistics | |
|---|---|
| Market cap | SEK 10.50b |
| Earnings (TTM) | SEK 315.92m |
| Revenue (TTM) | SEK 1.46b |
Is BIOG B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOG B income statement (TTM) | |
|---|---|
| Revenue | SEK 1.46b |
| Cost of Revenue | SEK 399.14m |
| Gross Profit | SEK 1.06b |
| Other Expenses | SEK 747.37m |
| Earnings | SEK 315.92m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 12, 2026
| Earnings per share (EPS) | 3.12 |
| Gross Margin | 72.71% |
| Net Profit Margin | 21.60% |
| Debt/Equity Ratio | 0% |
How did BIOG B perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/27 09:16 |
| End of Day Share Price | 2025/10/27 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioGaia AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Uhde | ABG Sundal Collier Sponsored |
| Mattias Häggblom | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |